EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

Maxime Borgeaud iD, Timothée Olivier iD, Jair Bar iD, Stephanie Pei Li Saw iD, Kaushal Parikh iD, Giuseppe Luigi Banna iD, Claudio De Vito iD, Jill Feldman iD, Xiuning Le iD, Alfredo Addeo iD

CA: A Cancer Journal for Clinicians · 2025-10 · 75 (5) · 387-409

DOI: 10.3322/caac.70024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 17.07.2025. Verfasst von Maxime Borgeaud und 9 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, University Hospital Geneva, Geneva, Switzerland. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Precision Medicine, Protein Kinase Inhibitors. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The discovery of activating mutations in the epidermal growth factor receptor ( EGFR ) gene has revolutionized the management of lung cancer, enabling the development of targeted tyrosine kinase inhibitors (TKIs). These therapies offer improved survival and reduced side effects compared with conventional treatments. Recent advancements have significantly reshaped the treatment paradigm for EGFR ‐mutant non‐small cell lung cancer. TKIs are now incorporated into the management of early stage and locally advanced disease, and phase 3 trials have explored combination strategies in metastatic settings. Although these intensified approaches improve progression‐free survival, they come with increased toxicity and higher costs, underscoring the need for precise patient selection to maximize benefit. Emerging data on biomarkers, such as co‐mutations and circulating tumor DNA, show promise for refining treatment decisions. In addition, significant progress in understanding resistance mechanisms to EGFR TKIs has broadened therapeutic options. This review provides a comprehensive overview of the current landscape of EGFR ‐mutant nonsmall cell lung cancer, highlighting recent breakthroughs and discussing strategies to optimize treatment based on the latest evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsPrecision MedicineProtein Kinase InhibitorsMutationHumansErbB ReceptorsMolecular Targeted Therapy

Stichwörter der Autor:innen

activating mutationsepidermal growth factor receptor (EGFR)non‐small cell lung cancer (NSCLC)tyrosine kinase inhibitors (TKIs)

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Oncology Department, University Hospital Geneva, Geneva, Switzerland.
  • Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel.
  • Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Division of Medical Oncology, National Cancer Center Singapore, Singapore.
  • Duke-National University of Singapore Medical School, National University of Singapore, Singapore.
  • Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Maxime Borgeaud, Timothée Olivier, Jair Bar, Stephanie Pei Li Saw, Kaushal Parikh, Giuseppe Luigi Banna, Claudio De Vito, Jill Feldman, Xiuning Le, Alfredo Addeo

Zitieren

APA

Borgeaud, M., Olivier, T., Bar, J., Saw, S. P. L., Parikh, K., Banna, G. L., De Vito, C., Feldman, J., Le, X., & Addeo, A. (2025). Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management. CA: A Cancer Journal for Clinicians, 75(5), 387-409. https://doi.org/10.3322/caac.70024

Vancouver

Borgeaud M, Olivier T, Bar J, Saw SPL, Parikh K, Banna GL, et al. Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management. CA: A Cancer Journal for Clinicians. 2025;75(5):387-409. doi:10.3322/caac.70024

BibTeX
@article{Borgeaud2025,
  author = {Borgeaud, Maxime and Olivier, Timothée and Bar, Jair and Saw, Stephanie Pei Li and Parikh, Kaushal and Banna, Giuseppe Luigi and De Vito, Claudio and Feldman, Jill and Le, Xiuning and Addeo, Alfredo},
  title = {Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management},
  journal = {CA: A Cancer Journal for Clinicians},
  year = {2025},
  volume = {75},
  number = {5},
  pages = {387--409},
  doi = {10.3322/caac.70024}
}
Kostenlos starten →